Flagship Ventures Fund V General Partner LLC
SEC-identified person · CIK 1724575 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Foghorn Therapeutics Inc. FHTX | Director | filed 2020 - 2026 |
| Sana Biotechnology, Inc. SANA | Officer | filed 2021 - 2023 |
| Sigilon Therapeutics, Inc. SGTX | Officer | filed 2020 - 2023 |
| Codiak Biosciences, Inc. CDAK | Officer | filed 2020 - 2022 |
| Omega Therapeutics, Inc. OMGA | Officer | filed 2021 - 2021 |
| Rubius Therapeutics, Inc. RUBY | Officer | filed 2021 - 2021 |
| Kaleido Biosciences, Inc. KLDO | Director | filed 2019 - 2019 |
| Evelo Biosciences, Inc. EVLO | Officer | filed 2018 - 2018 |
| Denali Therapeutics Inc. DNLI | Officer | filed 2017 - 2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.